spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

Pharma Packaging and Labeling East Coast 2018

21-22 February 2018
Philadelphia, USA

Working together to successfully manage both creative and regulatory demands while safeguarding your products and protecting your patients

The 10th Annual Pharma Packaging and Labeling East Coast event aims to create an environment where commercial packaging and labelingteams work together to successfully manage both creative and regulatory demands while safeguarding products and protecting patients. To achieve this we have brought together top industry leaders whose experience will enable you to make this a reality. 

This year we will be exploring topics which affect both commercial labelling and packaging teams across small, medium and large pharma. We will have a co-presentation looking at the industries end-to-end labeling strategy to ensure companies are inspection readywhile harnessing branding as a storytelling thetool to remain relevant to your consumers, old and new. Coupled with this we aim to show ways through which the operational challenges of serialization can be overcome and improved to ensure you are meeting compliance standards. We are also happy to announce that the Drug Enforcement Administration will be returning, offering an opportunity to hear a different perspective on ways that pharma can serve the public health.

We look forward to welcoming you to Philadelphia on the 21st and 22nd of February 2018 for what is sure to be another year of insightful, interactive and informative panels, roundtables and presentations on issues in commercial packaging and labelling which matter to you!
 
Print this page
Send to a friend
   
spacer
Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>


News and Press Releases

Sustainability, plastics and Brexit: Keynote speakers set to inspire at PPMA Total Show 2019

Experts from IKEA, the British Plastics Federation and The Sunday Times to create a forum for education, knowledge-sharing and debate
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement